SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mankind Pharma informs about receipt of request for reclassification of shareholding

28 Oct 2023 Evaluate
Pursuant to the provision of Regulation 31A(8)(a) of the SEBI Listing Regulations, Mankind Pharma has informed about receipt of request letter dated October 27, 2023, from EzeRx Health Tech, (enclosed herewith as Annexure) requesting reclassification from ‘Promoter and Promoter Group’ Category to ‘Public’ Category in terms of the provisions of Regulation 31A of the SEBI Listing Regulations. The said request will be placed before the board of directors in their ensuing meeting for their consideration and the Company will take all other necessary approvals in terms of Regulations 31A of the SEBI Listing Regulations. 

The above information is a part of company’s filings submitted to BSE.

Mankind Pharma Share Price

2123.20 18.50 (0.88%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×